Log in
NASDAQ:YMAB

Y-mAbs Therapeutics Stock Forecast, Price & News

$42.74
-0.62 (-1.43 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$41.46
Now: $42.74
$43.50
50-Day Range
$36.69
MA: $39.76
$43.36
52-Week Range
$14.16
Now: $42.74
$50.49
Volume148,190 shs
Average Volume207,200 shs
Market Capitalization$1.71 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Read More
Y-mAbs Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
Phone646-885-8505
Employees32

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.01 per share

Profitability

Net Income$-81,030,000.00

Miscellaneous

Market Cap$1.71 billion
Next Earnings Date11/5/2020 (Confirmed)
OptionableNot Optionable
$42.74
-0.62 (-1.43 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

How has Y-mAbs Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, YMAB shares have increased by 86.0% and is now trading at $42.74.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Y-mAbs Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Y-mAbs Therapeutics
.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Y-mAbs Therapeutics
.

How can I listen to Y-mAbs Therapeutics' earnings call?

Y-mAbs Therapeutics will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) posted its quarterly earnings data on Thursday, August, 6th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.32.
View Y-mAbs Therapeutics' earnings history
.

What price target have analysts set for YMAB?

9 analysts have issued twelve-month target prices for Y-mAbs Therapeutics' shares. Their forecasts range from $39.00 to $52.00. On average, they expect Y-mAbs Therapeutics' share price to reach $44.71 in the next twelve months. This suggests a possible upside of 4.6% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics
.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totaling 3,260,000 shares, an increase of 11.6% from the September 30th total of 2,920,000 shares. Based on an average daily volume of 151,200 shares, the days-to-cover ratio is currently 21.6 days. Currently, 13.2% of the company's shares are sold short.
View Y-mAbs Therapeutics' Short Interest
.

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), Stag Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. (Age 48)
  • Dr. Claus Juan Møller San Pedro, CEO & Director (Age 56)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer, CFO & Director (Age 47)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 44)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 68)

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.46%), DekaBank Deutsche Girozentrale (0.03%), BNP Paribas Arbitrage SA (0.02%), HighMark Wealth Management LLC (0.01%), Nisa Investment Advisors LLC (0.00%) and Pacer Advisors Inc. (0.00%). Company insiders that own Y-mAbs Therapeutics stock include Bo Kruse, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San and Thomas Gad.
View institutional ownership trends for Y-mAbs Therapeutics
.

Which major investors are buying Y-mAbs Therapeutics stock?

YMAB stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., DekaBank Deutsche Girozentrale, BNP Paribas Arbitrage SA, HighMark Wealth Management LLC, Nisa Investment Advisors LLC, and Pacer Advisors Inc.. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include James Healy, and Pedro Claus Juan Moller-San.
View insider buying and selling activity for Y-mAbs Therapeutics
.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $42.74.

How big of a company is Y-mAbs Therapeutics?

Y-mAbs Therapeutics has a market capitalization of $1.71 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.